The $5.1 billion U.S. meal replacements market has held up fairly well the past few years, despite strong competition for dieter dollars from the GLP-1 drugs, but they were affected. Growth is forecast for 2025 and 2028. As a DIY weight loss strategy, meal replacement shakes and nutrition bars are stillpopular, are easily accessible, inexpensive, and they don’t have side effects.
Companies selling meal replacements lost $1.5 billion in sales to the GLP-1 drugs market in 2023-2024 – mostof the loss from Medifast. Some competitors have added the GLP-1 drugs to their programs to position themselves for a new future. High protein meal replacements have been positioned as an adjunct to the weight loss drugs.
This Marketdata report is a completely updated analysis of the U.S. meal replacements and OTC appetite suppressants market -– how they have been affected by and are responding to the popular GLP-1 drugs. This is the most comprehensive investigation of the U.S. meal replacements market published by anyone worldwide.
Included… dollar value & growth rate of the market (early 1980s to 2024 and 2025 & 2028 forecasts), latest market trends and company developments, status reports for retail and MLM meal replacements and weight loss supplements, major distribution channels, and growth drivers. Analysis of retail versus MLM sales channels. Analysis of the medical weight loss programs market and competition from GLP-1 drugs.
Competitor profiles for: Medifast, Herbalife, Slim-Fast (Glanbia), Simply Good Foods (Atkins Nutritionals), BeachBody, Visalis Life Sciences, Isagenix, Shaklee, AMWAY (Quixtar), and Nu-Skin.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook